EN DE
Watch China Health Group for free: we tell you when fair value or trend changes.
Data-driven stock valuation

China Health Group (0673) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of China Health Group stock HK$0.24, price HK$0.35, that is 29.7% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN BMG2107P1059

CH China Health Group logo Thin data Nov 10, 2026

China Health Group

0673 · HK
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Mixed Growth (revenue 5y −14.1 %/yr in HKD)
Fair value HK$0.2424 · Overvalued
Quality 30/100
Loss-making · -116.7% net margin (TTM)
High debt
Negative free cash flow
Trails peers (1/10)
Narrow moat 12/100
Thin data
Estimate⚠ Thinly traded
Watch China Health Group for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$1.45 HK$0.1121 Fair Value HK$0.2424 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.1121 – HK$1.45 · fair‑value band HK$0.1818 – HK$0.3030 · the HK$0.3450 price screens above the HK$0.2424 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow China Health in your weekly email

Every Wednesday you see whether China Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

China Health Group Limited, an investment holding company, engages in the distribution and services of medical equipment and consumables in the People's Republic of China.

Show moreShow less

The company operates through four segments: Distribution and Service in Medical Equipment and Consumables; Hospital Operation and Management Services; Business Service; and Research and Development and Sale of Functional Food. It also provides healthcare hospital management services.

The company was formerly known as China HealthCare Holdings Limited and changed its name to China Health Group Limited in September 2015. China Health Group Limited is headquartered in Central, Hong Kong.

Stock analysis

China Health Group (0673) currently trades at HK$0.3450, while our estimate is HK$0.2424, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.1818 (bear) to HK$0.3030 (bull), the price of HK$0.3450 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.

China Health Group reported revenue of HK$41.1M in FY2026 versus HK$107M in FY2022, a compound −21.3%/yr. Reported net income was −HK$47.9M in FY2026.

Key figures

Market cap HK$478M (≈ $61.0M) Micro · P/S ratio 9.45 · Net margin −117% · Return on equity −159% · Return on assets (EBIT) −21.5% (5-year average) · Operating margin −107% · Revenue (TTM) HK$41.1M · Revenue growth (YoY) +6.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 58% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −30%, 0673 screens richer than that median.

Fair Value

Bear HK$0.1818 Fair Value HK$0.2424 Bull HK$0.3030
Price HK$0.3450 · Downside -29.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 22
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.
Revenue growth 1 year
+5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.1%
Start year 2021 (pandemic). Over 10 years: +5.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−12.9% (2021) → −110.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

0673 screens overvalued: fair value 30% below the price. Compare with McKesson Corporation →

Compare China Health Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −29.7% · Bottom 25%
Profitability
Return on assets −30.4% · Bottom 25%
Net margin (12 months) −116.7% · Bottom 25%
Operating margin (12 months) −107.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.0% · Above median
Balance sheet
Debt / equity 4.24× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 8.98× · Priciest 25%
P/S (12 months) 11.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 39
FUTURE (revenue growth)30 · sector 21
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 54

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.05 HK$51.15 +200% vs 0673
Jointown Pharmaceutical Group 600998 ¥5.18 ¥11.56 +123% vs 0673
Shanghai Pharmaceuticals Holding 601607 ¥16.44 ¥35.78 +118% vs 0673
China National Medicines Corporation 600511 ¥28.70 ¥58.47 +104% vs 0673
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.72 ¥26.64 +35% vs 0673
Cencora, Inc COR $348.71 $341.58 −2% vs 0673
Henry Schein, Inc HSIC $88.74 $78.69 −11% vs 0673
McKesson Corporation MCK $1,083 $822.74 −24% vs 0673
Galenica AG GALE CHF 90.05 CHF 61.79 −31% vs 0673
Cardinal Health, Inc CAH $276.79 $163.14 −41% vs 0673

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Health Group: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "China Health Group Fair Value". https://www.fairvalue-calculator.com/stock/0673

Frequently asked questions

Is China Health Group (0673) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.2424 versus a price of HK$0.3450, about 30% lower (overvalued).
What is the fair value of 0673?
Our estimate for China Health Group is HK$0.2424 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.3450.
What is the quality score of 0673?
China Health Group has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Health Group (0673)?
Our calculated price target is the estimate of HK$0.2424 (as of Nov 10, 2026). Cautious scenario HK$0.1818, optimistic scenario HK$0.3030. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the China Health Group stock forecast for 2026?
Our estimate puts fair value at HK$0.2424, about 30% lower versus a price of HK$0.3450 (overvalued). Cautious scenario HK$0.1818, optimistic scenario HK$0.3030. The calculation is refreshed regularly with new filings.
What is the revenue of China Health Group (0673)?
China Health Group reported trailing-twelve-month revenue of about HK$41.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of China Health Group (0673)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Health Group it is HK$0.2424 per share (as of Nov 10, 2026), against a price of HK$0.3450.
Is China Health Group stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 0673 trades above its calculated fair value: price HK$0.3450, fair value HK$0.2424, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0673?
No. The price is what the market pays today (HK$0.3450); the fair value is what the company's own numbers justify (HK$0.2424). For China Health Group the two are HK$0.1026 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Health Group worth?
The market values China Health Group at about HK$478M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.3450; our models calculate a fair value of HK$0.2424 per share.
What do the bullish and bearish scenarios say about 0673?
Our models span a range for China Health Group: cautious scenario HK$0.1818, base HK$0.2424, optimistic HK$0.3030 per share (as of Nov 10, 2026, price HK$0.3450). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Health Group (0673)?
Balance-sheet figures for China Health Group (as of Nov 10, 2026): return on equity −158.9%, debt of 4.24 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 0673 from its 52-week high?
China Health Group trades at HK$0.3450, about 58% below its 52-week high of HK$0.8200 and 33% above the low of HK$0.2600 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2424 is for.
Which stocks are comparable to China Health Group?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Health Group stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.3450, calculated fair value HK$0.2424 (−30%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. China Health Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Health Group (0673)?
The closing price on Nov 10, 2026 was HK$0.3450. Our estimate is HK$0.2424, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Health Group right now?
The price sits above even our optimistic bull case (HK$0.3030). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of China Health Group

How large is the market capitalisation of China Health Group (0673)?
The market capitalisation of China Health Group is HK$478M (≈ $61.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Health Group (0673)?
The price-to-sales ratio of China Health Group is 9.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of China Health Group (0673)?
The net margin of China Health Group is −117% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Health Group (0673)?
The return on equity (ROE) of China Health Group is −159% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Health Group (0673)?
On an EBIT basis the return on assets of China Health Group is −21.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Health Group (0673)?
The operating margin of China Health Group is −107% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Health Group (0673)?
Revenue at China Health Group is growing +6.0% versus a year earlier (3y avg −18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does China Health Group (0673) generate?
The free cash flow of China Health Group is −HK$86.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does China Health Group (0673) hold?
China Health Group holds more cash than debt, HK$17.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch China Health Group in the live analysis

One click puts China Health Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.